• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

    10/15/21 6:10:42 PM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TAK alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    TAKEDA PHARMACEUTICAL CO LTD

    (Last) (First) (Middle)
    1-1, NIHONBASHI-HONCHO 2-CHOME

    (Street)
    CHUO-KU, TOKYO M0 103-8668

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/06/2021
    3. Issuer Name and Ticker or Trading Symbol
    Theseus Pharmaceuticals, Inc. [ THRX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Series A Preferred Stock (1) (1) Common Stock 1,615,427 (1) I See explanation(2)(3)
    1. Name and Address of Reporting Person*
    TAKEDA PHARMACEUTICAL CO LTD

    (Last) (First) (Middle)
    1-1, NIHONBASHI-HONCHO 2-CHOME

    (Street)
    CHUO-KU, TOKYO M0 103-8668

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    ARIAD PHARMACEUTICALS INC

    (Last) (First) (Middle)
    40 LANDSDOWNE STREET

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    Explanation of Responses:
    1. These shares of the Issuers Series A Preferred Stock are expected to convert on a one-for-one basis into the number of shares of the Issuers common stock, par value $0.0001 per share (Common Stock), shown in Column 3 immediately upon the closing of the Issuers initial public offering without payment of additional consideration. The Series A Preferred Stock has no expiration date.
    2. This statement is being filed jointly by Takeda Pharmaceutical Company Limited and ARIAD Pharmaceuticals, Inc.
    3. Takeda Pharmaceutical Company Limiteds beneficial ownership of the reported securities is comprised of 1,615,427 shares of Series A Preferred Stock held by ARIAD Pharmaceuticals, Inc. ARIAD Pharmaceuticals, Inc., is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.3%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
    Remarks:
    /s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company Limited 10/06/2021
    /s/ Paul Sundberg, Attorney-in-Fact for ARIAD Pharmaceuticals, Inc. 10/06/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TAK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TAK

    DatePrice TargetRatingAnalyst
    4/2/2025Equal-Weight → Overweight
    Morgan Stanley
    3/16/2023$20.00Neutral → Buy
    BofA Securities
    7/19/2022$21.00 → $24.00Market Perform → Outperform
    Cowen
    10/7/2021Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TAK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Takeda Pharma upgraded by Morgan Stanley

      Morgan Stanley upgraded Takeda Pharma from Equal-Weight to Overweight

      4/2/25 8:46:19 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Pharma upgraded by BofA Securities with a new price target

      BofA Securities upgraded Takeda Pharma from Neutral to Buy and set a new price target of $20.00

      3/16/23 7:24:52 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Pharma upgraded by Cowen with a new price target

      Cowen upgraded Takeda Pharma from Market Perform to Outperform and set a new price target of $24.00 from $21.00 previously

      7/19/22 7:32:25 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

      GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency1 U.S. Commercialization of GAMMAGARD LIQUID ERC Projected to Begin in 2026 Company Announces Future Manufacturing Discontinuation End Date for Takeda's First-Generation Low-IgA Product, A Freeze-Dried Formulation in Company's Differentiated Immunoglobulin Portfolio of Ready-to-Use Liquids2 Takeda ((TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µ

      6/30/25 8:00:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Announces New Assignments of Directors

      Takeda (TYO:4502, NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs. Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and acti

      6/25/25 3:07:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

      - Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma - ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy Compared to eBEACOPP, a Standard of Care Regimen in Europe - Second Approval in Frontline Hodgkin Lymphoma Broadens ADCETRIS' Therapeutic Reach, Adding to Six Previously Approved, Distinct Indications for ADCETRIS in the European Union Takeda ((TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with ne

      6/3/25 10:12:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 840,500 shares (Amendment)

      3/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      5/9/22 6:10:39 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Takeda Pharmaceutical Co Ltd claimed ownership of 500,000 shares

      3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      4/29/22 6:02:17 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Takeda Pharmaceutical Co Ltd

      3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Reporting)

      10/21/21 8:40:37 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Vatroslav Mateljic Appointed General Manager of Takeda Canada

      Vatroslav Mateljic's innovative approach and commitment to transforming the lives of patients will strengthen Takeda's leadership position in the Canadian biopharmaceutical sectorTORONTO, Sept. 16, 2024 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Vatroslav (Vatro) Mateljic as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Mr. Mateljic has held a number of executive leadership roles in sales, marketing and country management over his 25-year career in the pharmaceutical industry.  Mos

      9/16/24 8:39:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

      Takeda (TYO:4502, NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024. Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave

      3/26/24 7:07:00 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

      2024 Award Celebrates Outstanding Research in Cancer Immunology Winners Discovered Novel Connections Between the Immune System and Cancer Recipients Each Receive Unrestricted USD 200,000 Awards Takeda ((TAK) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology. Each winner receives an unrestricted prize of USD 200,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205723166/en/ The 2024 Senior Scientist winner is Robert D. Schre

      12/5/23 8:00:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/6/24 9:36:34 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/5/24 6:24:58 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Takeda Pharmaceutical Company Limited (Amendment)

      SC 13G/A - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Subject)

      2/7/23 2:10:49 PM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    SEC Filings

    See more
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      7/2/25 10:33:09 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      7/1/25 6:03:36 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Takeda Pharmaceutical Company Limited

      6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)

      6/30/25 6:06:46 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TAK
    Financials

    Live finance-specific insights

    See more
    • Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

      Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

      6/1/25 8:00:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

      Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 Takeda ((4502, NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products o

      5/8/25 2:36:00 AM ET
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

      − Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study Protagonist Therapeutics, Inc. ("Protagonist") ((PTGX) and Takeda ((TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all fou

      3/3/25 6:45:00 AM ET
      $PTGX
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care